Immunopeptide therapy, specifically the Generation 1 Personalized Edited Sequence (G1-PES) vaccine, has demonstrated significant clinical improvements in treating severe metastatic cancer. Dr. John Catanzaro’s clinic administered this personalized vaccine to 43 terminal-stage cancer patients between 2001 and 2014, showing promising results.
The patients involved were considered terminal, with life expectancy ranging from 3 to 4 months. They underwent an 18-month G1-PES therapy program aiming for remission and cancer-free survival. This treatment consisted of four cycles every 12 weeks. The study assessed safety and efficacy through adverse events, progression-free survival (PFS), and overall survival (OS).
The G1-PES vaccine was found to be safe, with no serious adverse effects reported. Minor reactions included slight fever, flu-like symptoms, and rash at the injection site, all of which were self-limiting. Patients experienced significant improvements in quality of life within 1-3 weeks of starting the therapy, with a notable reduction in cancer symptoms and clinical evidence of cancer regression (p<0.001).
The study reported an average tumor regression of 58.37% ± 32.25% and an extended survival of 5.78 ± 2.7 years across all cancer types treated. Specifically, lymphoma patients exhibited the highest response with 90.0 ± 14.1% tumor regression, followed by prostate cancer patients with 80.0 ± 28.3% regression. The treatment was well-tolerated, with no severe adverse events, and resulted in improved quality of life scores averaging 7.3 ± 2.5 on a 10-point scale.
The G1-PES vaccine targets tumor neoantigens, leveraging the body’s T cell-mediated immune response to attack cancer cells while minimizing damage to healthy tissues. This approach has shown broad anti-tumor efficacy across various cancer types, making it a versatile and effective treatment option.
The G1-PES vaccine has proven to be a feasible, safe, and effective therapy for patients with advanced metastatic cancer. Its ability to significantly improve quality of life and extend survival, coupled with minimal side effects, highlights its potential as a powerful tool in cancer immunotherapy.
This innovative treatment underscores the potential of personalized immunotherapy in transforming cancer care, providing hope for patients with previously limited options.
Are you ready to explore what therapies are available for advanced cancer care in a supportive environment? Our intensive program is designed for individuals seeking a personalized, integrative approach to cancer care. We collaborate closely with your conventional treatment schedule to optimize therapeutic synergies. To determine if our program aligns with your needs, please complete the form below.
Our dedicated team will promptly reach out to discuss your options. Contact us today to learn more about how The Karlfeldt Center’s Integrative Oncology Program can help guide you through your cancer journey toward renewed health and vitality.
Considering integrative cancer care? Learn seven questions to ask about evidence, safety, costs, and coordination before your first consultation.
Epigallocatechin-3-gallate (EGCG), a powerful polyphenolic compound found abundantly in green tea, has gained significant attention for its potential role in cancer prevention and therapy. Research published in Molecules provides an in-depth look into how EGCG may exert anti-cancer effects and
TWO DIFFERENT ENERGY SOURCES | Treatment protocols are not interchangeable PDT uses light; SDT uses ultrasound Photodynamic therapy (PDT) A photosensitizing medicine is activated by a specific light source in a defined treatment area. Light penetration is limited, so use
Explore Dr. Michael Karlfeldt’s integrative perspective on cancer care and therapies such as PDT, with questions to discuss alongside conventional oncology.